Evidence map›Paper›PMID 39434178›Full record

ArticleMicrobiome2024

Next-generation IgA-SEQ allows for high-throughput, anaerobic, and metagenomic assessment of IgA-coated bacteria.

Merel van Gogh, Jonas M Louwers, Anna Celli, Sanne Gräve, Marco C Viveen, Sofie Bosch, Nanne K H de Boer, Rik J Verheijden, Karijn P M Suijkerbuijk, Eelco C Brand and 3 more

Abstract read
In one paragraph

Article in Microbiome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Merel van Gogh *Medical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands.
Jonas M Louwers *Department of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands.
Anna CelliMedical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands.
Sanne GräveMedical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands.
Marco C ViveenMedical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands.
Sofie BoschDepartment of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Nanne K H de BoerDepartment of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism Research Institute, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Rik J VerheijdenDepartment of Medical Oncology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
Karijn P M SuijkerbuijkDepartment of Medical Oncology, UMC Utrecht, Utrecht University, Utrecht, The Netherlands.
Eelco C BrandDepartment of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands.
Janetta TopMedical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands.
Bas Oldenburg *Department of Gastroenterology and Hepatology, UMC Utrecht, Utrecht, The Netherlands.
Marcel R de Zoete *Medical Microbiology Department, UMC Utrecht, Utrecht, The Netherlands. M.R.deZoete-2@umcutrecht.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe intestinal microbiota plays a significant role in maintaining systemic and intestinal homeostasis, but can also influence diseases such as inflammatory bowel disease (IBD) and cancer. Certain bacterial species within the intestinal tract can chronically activate the immune system, leading to low-grade intestinal inflammation. As a result, plasma cells produce high levels of secretory antigen-specific immunoglobulin A (IgA), which coats the immunostimulatory bacteria. This IgA immune response against intestinal bacteria may be associated with the maintenance of homeostasis and health, as well as disease. Unraveling this dichotomy and identifying the immunostimulatory bacteria is crucial for understanding the relationship between the intestinal microbiota and the immune system, and their role in health and disease. IgA-SEQ technology has successfully identified immunostimulatory, IgA-coated bacteria from fecal material. However, the original technology is time-consuming and has limited downstream applications. In this study, we aimed to develop a next-generation, high-throughput, magnet-based sorting approach (ng-IgA-SEQ) to overcome the limitations of the original IgA-SEQ protocol.

resultsWe show, in various settings of complexity ranging from simple bacterial mixtures to human fecal samples, that our magnetic 96-well plate-based ng-IgA-SEQ protocol is highly efficient at sorting and identifying IgA-coated bacteria in a high-throughput and time efficient manner. Furthermore, we performed a comparative analysis between different IgA-SEQ protocols, highlighting that the original FACS-based IgA-SEQ approach overlooks certain nuances of IgA-coated bacteria, due to the low yield of sorted bacteria. Additionally, magnetic-based ng-IgA-SEQ allows for novel downstream applications. Firstly, as a proof-of-concept, we performed metagenomic shotgun sequencing on 10 human fecal samples to identify IgA-coated bacterial strains and associated pathways and CAZymes. Secondly, we successfully isolated and cultured IgA-coated bacteria by performing the isolation protocol under anaerobic conditions.

conclusionsOur magnetic 96-well plate-based high-throughput next-generation IgA-SEQ technology efficiently identifies a great number of IgA-coated bacteria from fecal samples. This paves the way for analyzing large cohorts as well as novel downstream applications, including shotgun metagenomic sequencing, culturomics, and various functional assays. These downstream applications are essential to unravel the role of immunostimulatory bacteria in health and disease. Video Abstract.

Indexed as

BacteriaFecesGastrointestinal MicrobiomeImmunoglobulin AMetagenomicsHigh-Throughput Nucleotide SequencingHumansInflammatory Bowel DiseasesImmunoglobulin ACancerCulturomicsGut microbiotaHigh-throughputIgA-coated bacteriaIgA-SEQInflammatory bowel diseaseIntestinal inflammationMetagenomic shotgun sequencingNext-generation IgA-SEQ

Identifiers

PMID39434178
PMCPMC11492651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.